Tanvex BioPharma, Inc. announced resignation of Peter Lin as financial officer and appointed Kevin Yeh as financial officer with effect on November 01, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
41.05 TWD | -2.26% |
|
-3.07% | -36.94% |
May. 28 | Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index | CI |
May. 13 | Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-36.94% | 208M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- 6541 Stock
- News Tanvex BioPharma, Inc.
- Tanvex BioPharma, Inc. Announces Management Changes